AC Immune (ACIU) Other Non Operating Income (2016 - 2026)
AC Immune (ACIU) posted quarterly Other Non Operating Income of -$224752.8 for Q1 2026, up 30.8% year-over-year from -$171832.2 in Q1 2025, and up 38.06% quarter-over-quarter from -$362839.2 in Q4 2025.
Analysis
AC Immune (ACIU) Other Non Operating Income (2016 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Other Non Operating Income for 11 consecutive years, with -$224752.8 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 30.8% year-over-year to -$224752.8; the TTM figure through Mar 2026 stood at -$3.3 million (up 16.87% YoY), while the FY2025 annual figure was -$3.4 million, down 85.33% from the prior year.
- Other Non Operating Income climbed to -$224752.8 in Q1 2026 per ACIU's latest filing, from -$362839.2 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $2.2 million in Q4 2024 and bottomed at -$3.1 million in Q3 2024.
- Historically, Other Non Operating Income has averaged -$354599.2 across 5 years, with a median of -$55139.3 in 2023.
- On a YoY basis, Other Non Operating Income climbed as much as 3451.49% in 2024 and fell as far as 15460.19% in 2024.
- AC Immune's Other Non Operating Income stood at -$113144.4 in 2022, then slumped by 861.51% to -$1.1 million in 2023, then jumped by 306.19% to $2.2 million in 2024, then sank by 116.18% to -$362839.2 in 2025, then jumped by 38.06% to -$224752.8 in 2026.
- Business Quant data shows ACIU's Other Non Operating Income at -$224752.8 in Q1 2026, -$362839.2 in Q4 2025, and -$15001.3 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | AC Immune | 285.63 Mn | 285.63 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 722,451.53 |
| Mar 31, 2026 | -224,752.82 |
| Dec 31, 2025 | -362,839.24 |
| Sep 30, 2025 | -15,001.31 |
| Jun 30, 2025 | -2.67 Mn |
| Mar 31, 2025 | -324,777.16 |
| Dec 31, 2024 | 2.24 Mn |
| Sep 30, 2024 | -3.08 Mn |
| Jun 30, 2024 | -2.77 Mn |
| Mar 31, 2024 | 1.85 Mn |
| Dec 31, 2023 | -1.24 Mn |
| Sep 30, 2023 | 75,854.22 |
| Jun 30, 2023 | -17,794.81 |
| Mar 31, 2023 | -55,139.29 |
| Dec 31, 2022 | -113,144.39 |
| Sep 30, 2022 | 17,602.76 |
| Jun 30, 2022 | 358,211.09 |
| Mar 31, 2022 | 151,593.17 |
| Dec 31, 2021 | -405,603.78 |
| Sep 30, 2021 | 132,873.75 |